Amneal's CREXONT Shows Consistent Parkinson's Benefits in Phase 4 Trial — Amneal Pharmaceuticals, Inc.

Event summary

Amneal's Phase 4 ELEVATE-PD study (n=214) shows CREXONT® delivers 3+ hours of additional 'Good On' time for Parkinson's patients across prior treatments.
Patients switching from RYTARY® gained 3.03 hours of daily 'Good On' time and nearly doubled continuous 'Good On' intervals to 6.27 hours.
Interim results presented at ATRMD 2026 Congress reinforce CREXONT's differentiated extended-release profile.
Common adverse events included dizziness (8.2%), falls (6.9%), and nausea (6.5%).
FDA approved labeling update in May 2026 allowing capsule contents to be sprinkled on applesauce.

The big picture

Amneal's positive Phase 4 results position CREXONT as a potential market leader in extended-release Parkinson's treatments, competing directly with RYTARY. The study's real-world efficacy data comes as Parkinson's disease prevalence grows, creating demand for more effective symptom management solutions. The FDA's recent labeling update expands CREXONT's patient accessibility, potentially broadening its market reach.

What we're watching

Therapeutic Differentiation: Whether CREXONT can sustain its clinical advantage over RYTARY and other extended-release Parkinson's therapies.
Regulatory Flexibility: The impact of FDA's labeling update on CREXONT's accessibility for patients with swallowing difficulties.
Long-Term Efficacy: How 12-month follow-up data will shape CREXONT's positioning as a long-term Parkinson's disease management option.